NLST (.315) strong move ending the day - worth $1 on paper

VICL - influenza play not yet run - popped over $7 on heavy volume during last scare

NLST - now 0.30, worth $1

NLST 0.29 - getting action, worth way more on paper - check the balance sheet.

CVGI looks like we may have a runner!

CSAR .12 - eod action

CSAR - like it 0.115 - a tenth of cash???? Way too low.

watch WUHN (2.38) on china momo - solid numbers all around, good growth, but thin play - if you haven't played low floats, stay away, but little volume, these types can go nuts

CNTF - 1.59, plenty of time off my first alert $1.38-1.40

CNTF - gave you plenty of time at $1.40 - chase time - should run much higher

CNTF - starting @ hod

Watch CNTF off SCON momo

CVM 0.27 (shareholder letter off DNDN) - could see momo

TBSI - great numbers on earning - way above estimates

thats nasdaq....considering 1/2 the nasdaq is now under $1, is that really the way to go??? lol

WSTL 0.30 one of the cheapest pennies out there getting movement here - tons of cash, no debt

HYTM 0.32 bio flying on study results

WSTL - if further strength in the micros, watch here - mostly overlooked, but very strong balance sheet for a 0.31 stock. They are back in compliance, and have recent insider buys. 3:1 assets over liabilities - much more garbage has flown in the last week or so.

NIV...profitable china IPO with 600k float - next high flyer ala rch, efut, sino etc

NIV...china IPO with 600k float - next high flyer ala rch, efut, sino etc

ALTU (0.19) maybe good play off GNBT - cash around $1.60/share. phase 2 for adults completed, phase 2 for children starts this Q. Cash good at least to end of year.

PDO - into 3's...watch for momo - push to 4. 5's if oil pushes $50

Watch PDO for volume off oil move - was 30% higher few days ago, 50% few weeks ago - should easily see a pop to the $4's

AOB 0.25eps and beat revenue as well as phase 1 trial in the US - should be trading 100% higher

SWSI looks like found bottom - compare to BJS at $9 and its projected $1.19 eps vs $1.34 for SWSI....way too cheap

SWSI - another great looking earnings play - hit $1.64 eps for the year, .48 for the Q. Trading at a 3pe and was twice as high just a month ago. Should rise close to $10 in the next week or so. No reason for the drop besides pre-earnings jitters on bad market.

CEDC $7.37 huge earnings and great spot on chart - should see double digits in short term

MGI on the move $1.49 - huge earnings, working down debt, piles of cash - great opportunity here as should see over $2 easy - much better shape than this time last year when it was more than twice the price

MGI huge earnings @ 1.40 - should see over $2 easy

FBP bank laggard ($4.41) - continued profitability, insiders buying, heavy short position - no good reason for the depressed share price. Squeeze should get this back to $7 quick.

KERX ph 1/2 news at 0.15 - should get some notice today

will have to look - just did the quick pipeline scan...i'll report if i find it

MAPP - huge dump on failed trial but stabilizing here, tons of cash, good burn rate, & pipeline still intact - another in phase 3, 1 phase 2, another just starting phase 2...bounce to 3's expected.

NXG $1.45 strong gold play undervalued to peers - check fundamentals and recent PR's. With gold over $1000, people will be scrambling for these micros. Much better here than alot of the plays still losing 10's of millions

LZR - due...earnings early march, downside 0.50

ATHX - great spot on this stem-cell $1.77 cash, trading around 0.90 - was 33% higher last week and conference on deck next Tuesday. News will be coming for the sector and expect another push. Low volume selloff today, great buy opp.

ARTG - great earnings/fundamentals for a $2 - should be a must have in this environment

NGEN 0.1975 licensing news near bottom of chart

NGEN 0.189 news Nanogen Establishes Scandinavian Gene Synthesis as New Licensee for Molecular In Vitro Diagnostics


SAN DIEGO--(BUSINESS WIRE)--Nanogen, Inc. (Nasdaq: NGEN - News), developer of molecular and rapid diagnostic products, announced today that it has signed a licensing and supply agreement with Scandinavian Gene Synthesis (SGS) for use of the Company’s proprietary MGB Probe technology and synthetic nucleic acid chemistries including dyes and quenchers for use in human in vitro diagnostic testing. Under the licensing agreement, SGS will have rights to use their cGMP manufacturing capabilities to make and sell molecular diagnostic products incorporating the Nanogen molecular technology. Terms of the agreement include an upfront license fee and the commitment for Nanogen to supply component products for use by SGS in the design and manufacture of custom DNA oligonucleotides for the molecular IVD industry.


“The market for molecular diagnostics is growing at more than 20% per year,” said David Ludvigson, Nanogen’s President and Chief Operating Officer. “With more than 40 molecular diagnostic reagent and kit products in our portfolio and many additional licensees, it’s clear our proprietary nucleic acid chemistries have proven to be reliable building blocks for molecular biology applications. We believe that making our MGB technology widely available as the components of choice for PCR based diagnostics will help to grow the market; and enabling quality cGMP manufacturers like SGS to supply the market is part of our business strategy.”

BCON - several years of working with them to make this happen - real big news thrown in just before close - could see nice gap tomorrow, move towards 0.70